Zolinza (Vorinostat, SAHA, suberoylanilide hydroxamic acid) is a histone deacetylase (HDAC) inhibitor that binds directly to the catalytic site of the enzyme thereby blocking substrate access. It inhibits class I and class II HDACs at nanomolar concentrations (IC50 < 86 nM).
IUPAC Name: N-hydroxy-N'-phenyloctanediamide
Zolinza is a drug used to treat a type of cancer called cutaneous T-cell lymphoma, also called CTCL. Zolinza is used in patients when the CTCL gets worse, does not go away, or comes back after treatment with other medicines.
CTCL, a type of non-Hodgkin's lymphoma, is a slow-growing form of cancer in which some of the body's white blood cells known as T-lymphocytes or T-cells become malignant. Normal T-cells function by regulating the body's immune system in its job of fighting infections and other foreign antigens. In CTCL, the malignant T-cells are drawn to the skin, where some are deposited.
© 2010-2017 www.hdacis.com